- Home
- DDI vs YMAB Comparison
DDI vs YMAB Comparison
Compare DDI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- YMAB
- Stock Information
- Founded
- DDI 2008
- YMAB 2015
- Country
- DDI South Korea
- YMAB United States
- Employees
- DDI N/A
- YMAB N/A
- Industry
- DDI EDP Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DDI Technology
- YMAB Health Care
- Exchange
- DDI Nasdaq
- YMAB Nasdaq
- Market Cap
- DDI 472.2M
- YMAB 386.7M
- IPO Year
- DDI 2021
- YMAB 2018
- Fundamental
- Price
- DDI $9.38
- YMAB $8.61
- Analyst Decision
- DDI Strong Buy
- YMAB Buy
- Analyst Count
- DDI 5
- YMAB 10
- Target Price
- DDI $19.60
- YMAB $13.91
- AVG Volume (30 Days)
- DDI 49.7K
- YMAB 842.3K
- Earning Date
- DDI 11-10-2025
- YMAB 11-07-2025
- Dividend Yield
- DDI N/A
- YMAB N/A
- EPS Growth
- DDI N/A
- YMAB N/A
- EPS
- DDI 2.15
- YMAB N/A
- Revenue
- DDI $333,256,000.00
- YMAB $85,385,000.00
- Revenue This Year
- DDI $16.04
- YMAB N/A
- Revenue Next Year
- DDI $6.72
- YMAB $13.97
- P/E Ratio
- DDI $4.32
- YMAB N/A
- Revenue Growth
- DDI 0.24
- YMAB N/A
- 52 Week Low
- DDI $8.09
- YMAB $3.55
- 52 Week High
- DDI $18.21
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- DDI 45.72
- YMAB 81.21
- Support Level
- DDI $9.20
- YMAB $8.50
- Resistance Level
- DDI $9.74
- YMAB $8.56
- Average True Range (ATR)
- DDI 0.22
- YMAB 0.02
- MACD
- DDI -0.02
- YMAB -0.13
- Stochastic Oscillator
- DDI 19.15
- YMAB 112.50
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.